Relapsed/Refractory Classical Hodgkin Lymphoma
1 clinical trials · Condition
◉ Watch Relapsed/Refractory Classical Hodgkin Lymphoma
| Record | Firm | Date |
|---|---|---|
| Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma (NCT05243693) | National Cancer Center, Korea | 2022-03-01 |
Track Relapsed/Refractory Classical Hodgkin Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.